Mangoceuticals, Inc. — Form 8-K Summary
Reporting date: March 25, 2024; filed March 26, 2024. The filing reports actions taken at a special stockholder meeting and does not provide operating or financial-period results.
Business Context and Corporate Actions
- Stockholders approved an amendment to the Company’s certificate of incorporation authorizing a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-50.
- The exact reverse-split ratio may be selected by the Board or an authorized committee at any time through March 25, 2025.
- Stockholders approved the First Amendment to the 2022 Equity Incentive Plan, which became effective upon approval.
- The amended plan permits incentive and nonqualified stock options, stock appreciation rights, restricted stock, restricted stock units, performance-based shares, and other equity-based awards.
Key Financial and Capitalization Information
- The filing does not provide revenue, earnings, cash flow, margins, debt, liquidity, or other operating financial metrics.
- The amended incentive plan currently provides for 10,000,000 shares, plus annual increases from April 1, 2024 through April 1, 2032, generally equal to the lesser of 10% of outstanding common stock or 2,000,000 shares.
- Total awards under the plan are capped at 26,000,000 shares, including a 26,000,000-share limit for incentive stock options.
Voting Results and Material Changes
| Proposal | For | Against | Abstentions | Broker Non-Votes | Outcome |
|---|---|---|---|---|---|
| Reverse stock split authorization | 15,396,470 | 1,352,013 | 56,851 | 223,940 | Approved |
| 2022 Equity Incentive Plan amendment | 11,837,917 | 706,612 | 148,916 | 4,335,829 | Approved |
| Meeting adjournment authority | 15,877,555 | 1,013,320 | 28,158 | 110,241 | Approved; no effect because Proposal 1 passed |
Shares representing 74.1% of voting shares outstanding on the February 28, 2024 record date were present in person or by proxy, constituting a quorum. The reverse-split proposal was approved by approximately 91% of votes cast.
Guidance, Outlook, Risks, and Unusual Items
- No financial guidance or operating outlook was provided.
- The reverse split could materially affect the number of outstanding shares and per-share trading characteristics, but the filing does not specify the final ratio or implementation date.
- The plan’s evergreen provision may increase potential equity dilution annually through 2032, subject to the overall 26,000,000-share cap and Board discretion to reduce an annual increase.
Investor Verification Checklist
- Verify whether and when the Board implements the reverse stock split and the ratio selected.
- Assess the resulting changes to shares outstanding, authorized shares, per-share data, and trading liquidity.
- Review the full amended equity plan for award terms, vesting conditions, and potential dilution.
- Confirm future equity issuances and annual evergreen increases against the 26,000,000-share aggregate cap.